Get all your news in one place.
100's of premium titles.
One app.
Start reading
Benzinga
Benzinga
Business
Lara Goldstein

Mindset Approved For Patent Application Involving Psilocin Derivatives For Central Nervous System Disorders

Mindset Pharma Inc. (OTCQB:MSSTF), a drug discovery & development company creating psychedelic medicines to treat neurological and psychiatric disorders, is currently working on four novel families of next-generation psychedelic compounds, as well as an innovative process to chemically synthesize psilocybin in addition to its own proprietary compounds. 

In recent years, the number of biotech, psychedelic-producer companies synthesizing compounds to treat specific health conditions grows at a remarkable pace. In this scenario, mental disorders seem to have a preferred treatment.  

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.